SPOTLIGHT: Glaxo wraps up Reliant buy

GlaxoSmithKline says it's completed its $1.65 billion buyout of U.S.-based heart drug specialist Reliant Pharmaceuticals; the Federal Trade Commission ended the mandatory antitrust waiting period early. Release

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.